Key Highlights

  • Third-quarter 2026 Revenue from continuing operations was USD 22.7 million, flat year over year.
  • Gross Margin was 61.8%, against 65% in the third quarter of 2025.
  • Net loss from continuing operations was USD 12.3 million, against USD 9.7 million.
  • Cash and cash equivalents totaled USD 31.7 million at September 30, 2026.

MDxHealth (NASDAQ:MDXH) reported third-quarter 2026 revenue of USD 22.71 million, against an estimate of USD 28.74 million. Loss per share was USD 0.16, against an estimate of USD 0.09. The company provides genomic and molecular diagnostic tests for urologic cancers, including Confirm, GPS and Exo mdx.

Chief Executive Officer Michael McGarrity said the third-quarter results fell short of the company's expectations. He attributed the quarter to temporary disruption in commercial execution, driven by accelerated turnover within the sales organization following the discontinuation of Resolve.

Commercial Restructuring

Mr. McGarrity said the company has initiated a restructuring of its commercial organization across sales, Marketing and client services. It eliminated the Chief Commercial Officer role and split sales and marketing into two operating groups, both reporting directly to him. He said the company has made progress backfilling and rebuilding its sales team and that it aims to exit the fourth quarter with a fully staffed sales organization positioned to return to growth in 2027.

In response to an analyst question, management said its goal is to return to the 20% top-line growth demonstrated for 18 quarters in a row. It cited average selling prices of USD 3,850 for GPS, USD 3,850 at Medicare rates, USD 2,000 for Confirm and USD 760 for Exo.

Financial Results

Interim Chief Financial Officer Ron Kalfus said that, following the wind-down of the Resolve UTI Business and the cessation of Plano, Texas laboratory operations before June 30, Resolve remains classified as a discontinued operation, and all figures discussed reflect continuing operations only.

Revenue from continuing operations was USD 22.7 million, flat against the third quarter of 2025. Tissue-based tests made up 79% of revenue, against 92% a year earlier, which management said reflects the integration of ExoDx liquid testing. Gross Profit was USD 14 million, a decrease of 5% from USD 14.8 million, and gross margin was 61.8%, against 65%. Management attributed the 3.2 percentage point reduction primarily to the shift in test mix toward liquid-based Volume following the ExoDx acquisition.

Operating expenses increased 16% to USD 22.2 million, producing an operating loss of USD 8.1 million, against USD 4.4 million. Management attributed the increase to the expanded footprint, headcount and operating expenses related to the ExoDx acquisition. Net loss from continuing operations increased 26% to USD 12.3 million, against USD 9.7 million. Adjusted EBITDA was negative USD 6.3 million, against negative USD 0.9 million. Cash and cash equivalents totaled USD 31.7 million at September 30, 2026.

Outlook Commentary

Management said it continues to Leverage peer-reviewed ProMPT data ahead of the ProtecT trial in collaboration with the University of Oxford, which it said carries the potential to change the market for GPS in the active surveillance setting. It said it is rolling out AI initiatives in the first half of 2027 intended to add value for urology and pathology stakeholders.

Mr. McGarrity described the company as a growth company focused exclusively on urologic cancers and said it continues to build its vertical of precision diagnostics, Confirm, GPS and Exo mdx, across the prostate cancer continuum. He said the company is committed to returning to the level of sales execution it delivered over the past four years.